Journal
NATURE REVIEWS IMMUNOLOGY
Volume 15, Issue 5, Pages 283-294Publisher
NATURE RESEARCH
DOI: 10.1038/nri3823
Keywords
-
Categories
Funding
- French state funds within the Investissements d'Avenir programme [ANR-11-IDEX-0004-02]
- European Research Council [322856]
- Assistance Publique - Hopitaux de Paris, France
- Sorbonne University, Pierre
- Marie Curie Medical School, Paris, France
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- Le Centre National de la Recherche Scientifique (CNRS)
- European Research Council (ERC) [322856] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Depletion of regulatory T (T-Reg) cells in otherwise healthy individuals leads to multi-organ autoimmune disease and inflammation. This indicates that in a normal immune system, there are self-specific effector T cells that are ready to attack normal tissue if they are not restrained by T-Reg cells. The data imply that there is a balance between effector T cells and T-Reg cells in health and suggest a therapeutic potential of T-Reg cells in diseases in which this balance is altered. Proof-of-concept clinical trials, now supported by robust mechanistic studies, have shown that low-dose interleukin-2 specifically expands and activates T-Reg cell populations and thus can control autoimmune diseases and inflammation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available